Single-cell transcriptomics reveals maturation of transplanted stem cell-derived retinal pigment epithelial cells toward native state
Bhav Harshad Parikh,Paul Blakeley,Kakkad Regha,Zengping Liu,Binxia Yang,Mayuri Bhargava,Daniel Soo Lin Wong,Queenie Shu Woon Tan,Claudine See Wei Wong,Hao Fei Wang,Abdurrahmaan Al-Mubaarak,Chai Chou,Chui Ming Gemmy Cheung,Kah Leong Lim,Veluchamy Amutha Barathi,Walter Hunziker,Gopal Lingam,Tim Xiaoming Hu,Xinyi Su
DOI: https://doi.org/10.1073/pnas.2214842120
2023-06-27
Abstract:Transplantation of stem cell-derived retinal pigment epithelial (RPE) cells is considered a viable therapeutic option for age-related macular degeneration (AMD). Several landmark Phase I/II clinical trials have demonstrated safety and tolerability of RPE transplants in AMD patients, albeit with limited efficacy. Currently, there is limited understanding of how the recipient retina regulates the survival, maturation, and fate specification of transplanted RPE cells. To address this, we transplanted stem cell-derived RPE into the subretinal space of immunocompetent rabbits for 1 mo and conducted single-cell RNA sequencing analyses on the explanted RPE monolayers, compared to their age-matched in vitro counterparts. We observed an unequivocal retention of RPE identity, and a trajectory-inferred survival of all in vitro RPE populations after transplantation. Furthermore, there was a unidirectional maturation toward the native adult human RPE state in all transplanted RPE, regardless of stem cell resource. Gene regulatory network analysis suggests that tripartite transcription factors (FOS, JUND, and MAFF) may be specifically activated in posttransplanted RPE cells, to regulate canonical RPE signature gene expression crucial for supporting host photoreceptor function, and to regulate prosurvival genes required for transplanted RPE's adaptation to the host subretinal microenvironment. These findings shed insights into the transcriptional landscape of RPE cells after subretinal transplantation, with important implications for cell-based therapy for AMD.